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The MICs of 24 antimicrobial agents were determined for 335 strains of Yersinia 
enter ocolitica isolated from faeces in the Netherlands during 1982-1991. The 
isolates belonged to biotypes 1A, IB, 2, 3, 4 and to serotypes 03, 05.27, 06.3, 07.8,
08, 09. Almost all strains were susceptible to piperacillin, piperacillin/tazobactam, 
imipenem, all cephalosporins except cefazolin, the aminoglycosides, quinolones, 
co-trimoxazole, doxycycline and chloramphenicol but resistant to amoxycillin, 
co-amoxiclav and macrolides. No association was observed between susceptibility 
patterns, biotype or serotype nor were there marked changes in the susceptibilty 
during the last decade. The agents traditionally used to treat human infection, 
including co-trimoxazole, doxycycline and chloramphenicol may remain drugs of first 
choice.
Introduction
Yersinia enter ocolitica is an enteric pathogen associated with a wide spectrum of clinical 
and immunopathological manifestations. Recognition as a human pathogen was soon 
followed by successful isolation from clinical specimens in many countries. The 
availibility of selective media and comprehensive identification and biotyping schemes 
contributed further to the detection of Y. enter ocolitica in stool specimens. Results of 
in-vitro antimicrobial susceptibilty testing of 7. enter ocolitica from different countries 
have been reported in several studies (Hornstein et al., 1985; Hoogkamp-Korstanje, 1987; 
Pham, Bell & Lanzarone, 1991a).
The aim of the present study was to evaluate the in-vitro activities of a wide range of 
antimicrobial agents, including the novel quinolone BAY y3118, against stool isolates of 
7. enter ocolitica, the relationship between antibiotic sensitivity and bio type, antibiotic 
sensitivity and serotype and to find out whether there has been any change in susceptibility 
during the last decade.
’“Phone: +31-(80)-614356; Fax: +31-(80)-540216.
0305-7453/95/110839 + 05 $12.00/0
839
© 1995 The British Society for Antimicrobial Chemotherapy
840 V. M. M. Stolk-Engelaar et al
Materials and methods
Bacteria
Three hundred and thirty-five strains of Y. enterocolitica isolated from stool specimens 
of patients with diarrhoea between January 1982 and July 1991 were used in this study 
(1982: 5 strains, 1983: 2, 1984: 26, 1985: 47, 1986: 75, 1987: 65, 1988: 56, 1989: 22, 1990:
22 and 1991: 15 strains). The strains were isolated in the Public Health Laboratory in 
Friesland (The Netherlands). One strain per patient was included in the study.
Culture methods
Stool specimens were inoculated on to Yersinia selective agar (Oxoid CM653 
PCH-Diagnostica, Haarlam, The Netherlands), deoxycholate citrate agar (Oxoid CM35 
PCH-Diagnostica) and into Rappaport broth. Plates were incubated at 22°C for 48 h. 
Broth was incubated at 22°C for 72 h and then subcultured on the above mentioned 
culture plates. Colonies resembling those of Yersinia spp. were identified according to 
Wauters (1973) and biotyped according to Wauters, Kandolo & Janssens (1987). Isolates 
were serotyped by slide agglutination using commercially available O-antisera for 03 and
09 (Sanofi Diagnostics Pasteur, Genk, Belgium) and with specific rabbit antisera for 
05.27, 06.3 and 08 (Hoogkamp-Korstanje et cil., 1992).
Antimicrobial agents
Standard powders were obtained from the following sources: Sigma (erythromycin, 
amoxycillin, piperacillin, cefazolin, gentamicin, amikacin), Bayer (ciprofloxacin, Bay 
y3118), Hoechst (ofloxacin), Hofmann-La Roche (fleroxacin, co-trimoxazole), Pfizer 
(azithromycin, doxycycline), Abbott (clarithromycin), Smith Kline Beecham (co- 
amoxiclav), Lederle (piperacillin/tazobactam), Merck Sharp & Dohme (imipenem), Glax 
(cefuroxime, ceftazidime), Bristol Myers Squibb (cefepime), Roussel UCLAF 
(cefpirome), Lilly (tobramycin), Gist-Brocades (chloramphenicol).
Determination of the MIC
The minimum inhibitory concentrations were determined in duplicate by broth dilution 
method in microtitration plates using Iso-Sensitest broth (Oxoid CM 491 
PCH-Diagnostica). Each well was filled with 150 fiL antibiotic solution except for the last 
well which was used to control growth. Inocula were prepared according to the direct 
colony suspension method recommended by the National Committee for Clinical 
Laboratory Standards (NCCLS, 1990), by suspending at least four colonies from 
overnight cultures on blood agar in 3 mL of sterile 0,85% NaCl to a McFarland turbidity 
standard of 0.5 (1.5 x 108 cfu/mL) inoculated into the microtiter plates with an automatic 
multipoint inoculator (MIC 2000, Dynatech, USA). Wells were inoculated with 1.5 ¿¿L 
suspension to yield 105 cfu/mL. The inoculum size and purity were controlled by plating 
1 /¿L of the bacterial suspension on to blood agar. The plates were incubated at 37°C for 
18 h. The MIC was defined as the lowest concentration to prevent visible growth, 
Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Staphylococcus 
aureus ATCC 29213 and Enterococcus faecalis ATCC 29212 were used as control 
organisms. For analysis, we adopted the breakpoints recommended by the Dutch 
working group on antimicrobial susceptibility testing (Mouton & van Klingeren, 1990).
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Results and discussion
The isolates were uniformly susceptible to piperacillin, piperacillin/tazobactam, 
imipenem, ceftazidime, cefepime, cefpirome, aminoglycosides, quinolones and 
co-trimoxazole (Table I). Almost all were susceptible to cefuroxime, cefdinir, doxycycline 
and chloramphenicol. All isolates were resistant to amoxycillin and most resistant to 
co-amoxiclav, cefazolin and the macrolides. The M IC 90S of BAY y3118 and ciprofloxacin 
were lower than those of ofloxacin and fleroxacin. It was also noteworthy that more 
strains were susceptible to azithromycin than to the other macrolides and that a high MIC 
of azithromycin corresponded with a high MIC of the other macrolides and vice versa.
The ranges of MICs of the different antimicrobial agents are in agreement with the data 
reported from other parts of the world (Hornstein et ah, 1985; Pham et al., 1991a).
Of 335 isolates, 139 strains belonged to serotype 03,76 strains to serotype 09,16 strains 
to serotype 5.27, 13 strains to serotype 06.3, 20 strains to serotype 07.8 and 22 strains 
to serotype 08. The remaining strains were not typeable with the antisera used. These 
findings are not different from the rest of Europe (Cover & Aber, 1989),
The sensitivities of strains to /Mactam antibiotics in vitro have been shown to 
correspond to the major serotypes (Hornstein et al., 1985) but we found no difference 
in the range of MICs within the serotypes for any of the antibiotics tested.
Table I. MICs (mg/L) of 24 antibiotics for 335 Y. enterocolitica isolates
Antibiotic
Breakpoint
concentration
(mg/L)fl MIC» MIC™ Range
%
Susceptible
Amoxycillin < 2 >32 >32 4-^32 0
Co-amoxiclav < 2/1 16 >32 <l->32 5
Piperacillin <16 2 8 <1-16 100
Piperacillin/tazobactam £16/4 1 4 <0.5-8 100
Imipenem <4 0.25 0.25 <0.031-0.5 100
Cefazolin <4 32 64 <2->64 10
Cefuroxime <4 2 4 <0.5-> 16 90
Ceftazidime <4 0.5 1 <0.062-4 100
Cefepime <4 0.032 0.032 <0.008-0.128 100
Cefdinir <4 4 8 <0.5-$* 16 86
Cefpirome <4 <0.5 <0.5 <0.5-2 100
Gentamicin <1 0.5 1 <0.125-2 99
Tobramycin < 1 0.5 1 <0.125-2 99
Amikacin <4 2 2 0.25-4 100
Ciprofloxacin <0.5 0.016 0.016 <0.008-0.032 100
Ofloxacin <0,5 0.064 0.064 <0.008-0.128 100
Fleroxacin <0.5 0.064 0.064 0.016-0.128 100
BAY y3118 <0.5 <0.008 <0.008 <0.008-0.016 100
Erythromycin < 2 32 64 <2-^64 2
Azithromycin < 2 2 4 0.5-8 50
Clarithromycin < 2 32 32 <2-128 3
Co-trimoxazole <2/38 <0.064 0.125 <0.064-0.25 100
Doxycycline <1 1 2 <0.125-8 90
Chloramphenicol <4 2 4 <0.5-8 94
"Recommended by Mouton & van Klingeren (1990) (except for azithromycin, clarithromycin, cefepime, 
cefdinir and cefpirome).
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Table II. Susceptibility of different Y. enterocolitica biotypes to various antibiotics (MIC50 in mg/L)
Biotype 1A Biotype IB Biotype 2 Biotype 3 Biotype 4
Antibiotic (77=71) (n =  43) (n ~ 34) (« = 21) (n — 134)
Amoxycillin >32 >32 >32 >32 >32
Co-amoxiclav >32 >32 >32 >32 8
Piperacillin 4 4 4 4 2
Piperacillin/tazobactam 2 2 2 2 <0.5
Imipenem 0.25 0.25 0.25 0.25 0.25
Cefazolin 16 16 16 8 16
Cefuroxime 2 4 4 4 2
Ceftazidime 0.5 0,5 0.5 0.5 <0.062
A biotype for 303 isolates could be determined. Pham et a l (1991a,b) found a specific 
relationship between biotype and sensitivity pattern to /3-lactam agents and suggested that 
differential sensitivity to the members of the p-lactam antibiotics was due to the 
production of different /?-lactamases by the members of each biotype. In the present study 
we could not demonstrate any obvious difference in the range of MICs of the ^-lactams 
for the various biotypes. The M IC50 for the biotypes are shown in Table II. The MIC50 
for biotype 4 to the combination of a /J-lactam with clavulanic acid or tazobactam was 
clearly lower than that of the other biotypes but there were only four strains of biotype
4 with a MIC < 1 mg/L for co-amoxiclav.
Finally, there was no significant change in the susceptibility patterns of the different 
isolates over the years and no multiply resistant isolates were found. In conclusion, our 
data show that the agents traditionally used to treat human infection, including 
co-trimoxazole, doxycycline and chloramphenicol may remain drugs of first choice,
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